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ABSTRACT 
 
  
Introduction: In 2015, the Australian Army commissioned a systematic review to assess the 
evidence on effectiveness and safety of pharmacological and biotechnological products for 
cognitive enhancement specifically in Army personnel. 
 
Methods: Searches for studies examining biotechnological and pharmacological products in 
Army populations were conducted in December 2015. Cochrane CENTRAL, MEDLINE, 
EMBASE, CINAHL and PsycINFO were searched; no date or language restrictions were 
applied. WHO’s International Clinical Trials Registry Platform and ClinicalTrials.gov were 
searched to identify ongoing trials. Studies meeting inclusion criteria were evaluated for risk 
of bias using the Cochrane Risk of Bias tool. Due to heterogeneity of findings, meta-analysis 
could not be conducted. Findings were synthesised narratively and by vote-counting method.  
 
Results: Sixteen pharmacological enhancement products were evaluated in 22 RCTs, 
involving 1,284 personnel in aggregate. Only 3 of the studies were published since 2010. 
The interventions evaluated were varied, including supplements (e.g. carbohydrate), 
stimulants (e.g. caffeine), and hormones (e.g. melatonin). Generally, caffeine provided an 
improvement in performance compared to placebo on 5 of 7 reported cognitive outcomes, 
followed by levothyroxine (4 cognitive outcomes) and prazosin (3 cognitive outcomes). 
Performance results were mixed (finding an improvement but also no effect in comparison to 
placebo) for caffeine and melatonin on 2 outcomes. No evidence was found pertaining to 
biotechnological products. Studies rarely reported safety outcomes (e.g., adverse events 
and addiction).  
 
Conclusion: Findings from this review need to be interpreted with considerable caution. 
Future studies should include outcome such as acute and long-term adverse events, and 
should evaluate cognitive performance using cognitive tests that are specific to the Army 
population. 
 
 
 
 
Keywords: pharmacological, biotechnological, performance-enhancement, army, systematic 
review 
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WHAT THIS PAPER ADDS 
 
 
What is already known on this subject? 
• Availability and use of cognitive enhancers in the form of pharmacologicals and 
biotechnologies is increasing 
• Substantial investment is being made in funding research involving pharmacologicals 
and biotechnologies to enhance the performance of service personnel 
What important gaps in knowledge exist on this topic? 
• The effectiveness, safety and other impacts of using cognitive enhancers in the Army 
population is unclear  
What this study adds  
• Evidence on the impacts of use of cognitive enhancers in the Army population is 
limited, inconsistent, and frequently poorly reported, precluding the ability to make 
recommendations 
• Harms such as acute and long-term effects of enhancers need to be more frequently 
assessed and reported when conducting studies in Army personnel 
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Performance-enhancing pharmacologicals and biotechnologies in the Army: a systematic review of the evidence 
 
INTRODUCTION  
 
Military combat and highly-intense military training requires resistance to physical and 
cognitive stress, as extended times of these operations and training exercises are 
associated with considerable physical and cognitive fatigue.(1) Therefore, substantial 
investment is being made in funding research involving biotechnological and 
pharmacological applications including in vitro therapeutic systems, in vivo therapies, and 
hybrid biological/device treatment systems to enhance the performance of service 
personnel. For example, the Defence Advanced Research Projects Agency (DARPA) in the 
USA has proposed to invest just under $US3 billion into developing enhancement 
technologies.(2) Based on publicly available information, one focus of DARPA appears to be 
on developing cognitive enhancers such as pharmacological products and biotechnologies.  
 
Pharmacological products (pharmacologicals) take the form of drugs, supplements, 
nutraceuticals, or functional foods. They include, for example, nootropic drugs (sometimes 
referred to as “smart drugs”), nootropic nutraceuticals, and other drugs and molecules. 
Specific nootropic drugs may include, but are not limited to, racetams (piracetam; 
pramiracetam; oxiracetam; coluracetam; aniracetam), stimulants (amphetamines, caffeine, 
methylphenidates, eugeroics, xanthins, nicotine), drugs for managing symptoms related to 
Alzheimer’s disease (acetylcholinesterase inhibitors, meclofenoxate / cenrophenoxine), and 
others (phosphatidylserine; tianeptine; L-theanine; valproate; phenylalanine).  Nootropic 
nutraceuticals may include, for example, creatine, omega 3 and various antioxidants. These 
pharmacologicals are thought to work directly on the receptors in the brain (e.g. N-methyl-D-
aspartate – NMDA – receptors), increasing the release of particular neurotransmitters that 
can transiently or in the short-term change the function of brain connections. They are 
mainly taken orally, but may also be injected, inhaled, or administered topically.(3, 4) 
 
Biotechnology can be defined as the use of living organisms, or their products, to create new 
ways to improve human health (medical biotechnology) and the environment. Performance-
enhancing biologicals / biopharmaceutical engineered products thus could include NMDA 
(NR2B) expression, oxygen (O2) enhancers (such as blood doping and erythropoietin 
(EPO)), and manufactured growth factors. Cell therapies, including tissue engineering, could 
be used to produce various growth factors for use as performance enhancers.(5)  
4 
This article has been accepted for publication in Journal of the Royal Army Medical Corps, 2018 following peer 
review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/jramc-2016-000752 
 
 
As performance-enhancing pharmacologicals and biotechnologies proliferate, it was 
considered necessary to consider the evidence of the products’ effects on the well-being and 
cognitive performance of service personnel. The Australian Army therefore commissioned a 
systematic review to assess the available evidence on the pharmacological and 
biotechnological products used for cognitive enhancement specifically in the Army 
population. The findings of this systematic review are presented here.  
 
METHODS 
 
Protocol 
 
A protocol for the systematic review was prepared by the authors, submitted for feedback to 
the Australian Army, and revised accordingly.  
 
Searches 
 
In December 2015, a systematic search was conducted of the following medical databases: 
The Cochrane Central Register of Controlled Trials (CENTRAL, Issue 12, 2015), MEDLINE 
(via OVID SP), EMBASE (via EMBASE.com), CINAHL (via EBSCOhost) and PsycINFO (via 
OVID SP). The search strategy is provided in Appendix 1.  
 
To identify ongoing trials, the World Health Organization’s International Clinical Trials 
Registry Platform (WHO ICTRP) and ClinicalTrials.gov were searched in June 2016.  
 
Inclusion and exclusion criteria 
 
The search results were screened for inclusion by four authors (in pairs of two). Any 
differences were resolved by consensus and consultation with a third author. The following 
inclusion and exclusion criteria were applied:  
 
Studies: only comparative interventional studies were included – randomised controlled 
trials (RCTs) and quasi-RCTs.  
 
Participants: The study population had to include Army personnel. Army personnel could be 
at any position or professional level within the Army (e.g. junior officers, senior officers, 
engineers). There were no restrictions on sex, age, or ethnic background. All settings were 
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included, ranging from training activities to active combat. The baseline status of the Army 
personnel included relatively healthy/stable individuals who may be under physical, mental, 
and/or emotional stress. Although physical, mental, and/or emotional stress may result in 
injury and impairment, studies where personnel had chronic, sustained, or serious injury or 
impairment that took them out of active duty were excluded. 
 
Interventions: Pharmacological products could take the form of drugs, supplements, 
nutraceuticals, or functional foods. Biologicals / biopharmaceutical engineered products 
could include NMDA (NR2B) expression, oxygen (O2) enhancers (such as blood doping and 
erythropoietin (EPO)), and manufactured growth factors. Cell therapies, including tissue 
engineering, could be used to produce various growth factors for use as performance 
enhancers. Excluded interventions were: genetic engineering technologies (e.g. gene 
therapy and genetic testing), biosensors and biomolecular sensors, biomedical devices, 
educational programmes, and computer hardware and software systems (this may include a 
whole range of decision aides, decision-making software, and analytical software). 
 
Comparators: Studies needed to compare the intervention(s) to either a different 
intervention(s), or the same intervention(s) at a different dose, placebo, or no treatment. 
 
Outcomes: Army-relevant cognitive performance measures were sought, and were grouped 
under the following 10 domains: 
1. Alertness (arousal / sleepiness) 
2. Attention (selective / focused / divided) 
3. Action control (action selection / initiation / maintenance / completion) 
4. Decision-making (perception / diagnosis / selection) 
5. Self-regulation and executive function (working memory / switching / inhibitory control) 
6. Memory (long term / procedural / declarative / working) 
7. Vigilance (threat detection / discrimination - response time / bias / sensitivity) 
8. Communication (language processing / implicit perception) 
9. Co-action (mental modelling / coordination) 
10. Stress resistance (threat appraisal) 
 
Other outcomes of interest included: safety (e.g. mortality, morbidity, addiction, and any 
adverse events), quality of life, and ethical issues (e.g., issues pertaining to autonomy, the 
right to object, dignity, etc.). 
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Data extraction 
 
Data from included studies was extracted and entered into evidence tables by three authors. 
The evidence tables collected the following information for each study: study design, country 
where the study was conducted, participant population (including sex and age), health status 
of the participants, condition of testing, intervention used (dose, frequency), comparator 
(dose, frequency), outcomes measured (including outcome definitions), cognitive tests used 
to assess the outcomes and associated results, adverse events, and any reporting of ethical 
issues in the studied populations. 
 
To link the outcomes reported in the included studies to the 10 cognitive outcome domains 
of interest, one author mapped each cognitive test to one or more cognitive outcome 
domains. For example, one cognitive test known as the Walter Reed Performance 
Assessment Battery was judged as measuring performance on 5 cognitive domains: 
alertness, attention, self-regulation and executive function, memory and vigilance. Given the 
considerable variability in the cognitive tests used, this approach of mapping tests to 
cognitive outcomes was viewed as the most pragmatic approach to synthesise the breadth 
of information.  
 
Risk of bias 
 
One author assessed and rated the risk of bias of each study across seven domains using 
Cochrane’s risk of bias tool.(6) These domains included: (1) random sequence generation, 
(2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of 
outcome, (5) incomplete outcome data, (6) selective outcome reporting and (7) any other 
potential sources of bias. Within each study, a domain was judged as having low risk of bias, 
high risk of bias or unclear risk of bias (e.g., due to a lack of information or uncertainty over 
the potential for bias). 
 
Synthesis 
 
Owing to the breadth of interventions used and variations in outcome measures, and in 
some cases poor reporting of the results, this review did not explicitly extract numerical data 
from dichotomous variables (e.g. correct or incorrect answer) or continuous variables (e.g. 
reaction time). In lieu of this, a summary of the direction of the results for each cognitive 
outcome was done by a vote-counting method.  
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For a particular cognitive outcome, a study that reported a superior performance result in the 
intervention group compared to the comparison group was given a score of either +2 
(meaning the results strongly favoured the intervention) or +1 (meaning the results favoured 
the intervention). This categorisation system was extended to include circumstances where 
a study would report all the sub-measure results for a particular cognitive test. If all of the 
sub-measure results were positive then the study was given a +2 on the cognitive outcome 
domain.  
 
Studies reporting no significant or meaningful difference between the effects of the 
intervention compared to the comparator were given a score of 0.  
 
In studies where the effect of the intervention was worse than the comparator for a particular 
outcome (or sub-measures of an outcome), the outcome was given a score of -1 (meaning 
the results favoured the comparator) or -2 (meaning the results strongly favoured the 
comparator).  
 
This categorisation system does not assign weightings to studies, and does not differentiate 
between those studies that reported one overall cognitive test result and those studies that 
reported many test results from the one cognitive battery. However, given the varied quality 
of study data, as well as the wide range of interventions evaluated by the included studies, 
this was deemed to be the most pragmatic method to convey a general overview of the 
results.  
 
RESULTS 
 
Results of the search 
 
The search yielded 3910 references. On de-duplication and screening of the references on 
title and abstract, 364 references were identified as potentially relevant and reviewed in full-
text. Of these, 22 studies (RCTs) met the inclusion criteria.  
 
General characteristics of the relevant studies 
 
The 22 included RCTs included 1,284 Army personnel in aggregate. The majority of the 
RCTs (19 out of 22) were conducted in the United States (994 personnel) and recruited 
males (over 75%). Only three studies were published since 2010, 10 between 2000 and 
2009, and the remaining were all published prior to 2000. The majority of the studies were 
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small – only four RCTs had a sample size greater than 100. One RCT evaluated an 
intervention (phenformin) that was removed from the market in 1978 by the Food and Drug 
Administration (FDA) in the United States. Sixteen pharmacological enhancement products 
were evaluated by the included studies; none of the included studies evaluated 
biotechnological products. 
 
Risk of bias assessment 
 
The quality of the included studies was assessed using the Cochrane risk of bias tool. This 
involved judging a study’s risk of bias (serious, uncertain or no risk) on a particular domain. 
Each domain had been selected based on epidemiological evidence that, if at risk, the 
believability of the result would be less certain (see Figure 3 in Appendix 2).   
 
In general, for the random sequence generation domain (i.e. whether the method of 
generating a random sequence was adequate or not), 20 out of 22 RCTs were deemed to be 
at uncertain risk of bias. Similarly, all 22 RCTs were at uncertain risk of bias for allocation 
concealment because none of the studies reported their methods. For the blinding of 
participants and personnel domain, 16 of 22 RCTs were at low or no risk of bias because the 
participants and investigators were unlikely to know the allocated treatment group. For 
blinding of outcome assessors, only 13 of 22 RCTs were judged at low risk of bias for 
outcomes such as self-reported mood profiles and 15 of 22 RCTs were judged at low risk of 
bias for outcomes that were ‘objective’ (meaning that there was little room for misinterpreting 
of the results). Three studies were at high risk of bias for failing to adequately analyse data, 
substantial missing data and selective reasoning for excluding participants. In terms of 
reporting all the outcomes intended, 20 RCTs reported the results for the outcomes listed in 
the methods section but 2 RCTs omitted to report outcome data.  
 
Interventions studied 
 
Sixteen unique interventions were used to assess cognitive performance on a range of 
cognitive tests. The interventions were broad-ranging, including benzodiazepines (for 
insomnia and anxiety), hormones (such as melatonin), stimulants (such as caffeine), 
steroids, tropane alkaloids (medication for motion sickness) and anti-diabetic medication 
(phenformin) which had been removed from the market by the FDA in 1978. 
 
The most frequently studied class of interventions was supplements, such as: carbohydrate 
supplements, creatine, iron, multivitamin/minerals, and protein (Table 1).  
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In terms of the total number of participants enrolled, the three most studied interventions for 
assessing cognitive performance were: (1) carbohydrate supplementation (302 personnel 
across 3 studies), (2) multivitamin and mineral supplementation (240 personnel in 1 study) 
and (3) iron supplementation (219 personnel in1 study).  
 
Out of the 16 interventions, only 4 (25%) were investigated by more than one study: caffeine 
(2 studies in the past 10 years), carbohydrate supplements (3 studies in the past 20 years), 
dexamethasone (2 studies in the past 20 years), and scopolamine (3 studies in the last 30 - 
40 years).  
 
Outcomes investigated 
 
Ten cognitive outcomes were investigated by the included studies: alertness, attention, 
vigilance, self-regulation and executive function, memory, action control, co-action, decision 
making, stress resistance and communication. The 5 most studied cognitive domains were: 
alertness, attention, self-regulation and executive function, memory, and vigilance (Figure). 
Each of these is discussed in more detail below.  
 
[insert figure 1 here] 
Figure1: Randomised controlled trials comparing total sample sizes, total number of studies, and number of 
interventions contributing to the evidence for each of the 10 cognitive outcomes 
 
Alertness 
 
Seventeen RCTs, involving 1,115 participants, reported results on one or more cognitive 
tests relevant to alertness (Figure 2). 
 
Three interventions showed an improvement in alertness, when compared to placebo: 
prazosin, multivitamin and mineral supplementation, and levothyroxine. A study in active-
serving Army personnel with PTSD found that performance on four cognitive tests (Cognitive 
Affective Processing System or CAPS, CAPS hyperarousal cluster, global function, and 
sleep data) strongly favoured prazosin over placebo.(7) In general Army personnel during 
sustained training, there was increased alertness (less sleepiness) after multivitamin and 
mineral supplementation than  placebo.(8) Levothyroxine showed better performance on the 
Profile of Mood States (POMS) test than the placebo group, amongst Army personnel in 
setting of cold exposure.(9)  
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Studies of five interventions – carbohydrate supplements,(10-12) caffeine,(13, 14) 
melatonin,(15) dexamethasone,(16, 17) and montelukast sodium(18) – showed mixed 
results, e.g. an improvement in performance when assessed by one cognitive test (e.g. 
Stroop test), but no improvement when assessed on another cognitive test (e.g. POMS).  
 
Three interventions showed no change in performance on alertness-related tests when 
compared to placebo: iron supplements,(19) creatine supplements,(20) and triazolam.(21)  
 
[insert Figure 2 here] 
Figure 1: Distribution of favourable, neutral, or unfavourable results from RCTs for cognitive tests for 
alertness, attention, self-regulation and executive function, memory and vigilance. 
 
Attention  
 
Fourteen RCTs, involving 888 participants, reported results on one or more cognitive tests 
relevant to attention (Figure 2). 
 
Three interventions showed an improvement on attention-related cognitive tests, compared 
to placebo or control: prazosin, protein supplement, and levothyroxine. In a study of 67 
active-serving Army personnel with PTSD, performance on a global function cognitive test 
strongly favoured prazosin over placebo.(7) A study of general Army personnel in simulated 
mountain skirmishes strongly favoured protein supplementation over carbohydrate 
supplementation (active control) in performance on choice visual reaction time test.(22) 
Finally, a study of general Army personnel in a cold exposure setting favoured levothyroxine 
group over the placebo group for performance on POMS test.(9)  
 
Studies of 3 interventions showed mixed results – that is, improvement or no change in 
performance on attention-related cognitive tests: temazepam,(23) caffeine,(13, 14), and 
melatonin.(15)  
 
Five interventions showed no change in performance on attention-related cognitive tests, 
when compared to either placebo or control: iron supplements;(19) carbohydrate 
supplements;(10-12) pyridostigmine bromide, diethyltoluamide, and permethrin;(24) creatine 
supplements;(20) and triazolam.(21)  
 
11 
This article has been accepted for publication in Journal of the Royal Army Medical Corps, 2018 following peer 
review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/jramc-2016-000752 
 
Self-regulation and executive function  
 
Twelve RCTs, involving 492 participants, reported results relevant to self-regulation and 
executive function (Figure 2). 
 
In comparison to placebo, three interventions showed an improvement in self-regulation and 
executive function: levothyroxine, prazosin, and caffeine. In a study of general Army 
personnel in cold exposure setting, levothyroxine group performed better on a matching-to-
sample task than placebo group.(9) In active-serving Army personnel with PTSD, the 
prazosin group performed better on a global function cognitive test than the placebo 
group.(7) General Army personnel under sustained training and sleep deprivation who were 
assigned to the caffeine group, had better marksmanship performance than the placebo 
group.(13)  
 
Studies of triazolam(21) and dexamethasone(16) showed conflicting results – improvement, 
no change, or decline in performance (in comparison to placebo) – depending on the 
cognitive test used to assess performance.   
 
Carbohydrate supplements;(11, 12) pyridostigmine bromide, diethyltoluamide, and 
permethrin;(24) and creatine supplements(20) showed no change in performance on self-
regulation and executive function tests, when compared to placebo.   
 
When compared to placebo, scopolamine showed reduced performance on self-regulation 
and cognitive function tests.(25, 26)  
Memory 
 
Nine RCTs, involving 448 participants, reported results on one or more cognitive tests 
relevant to memory (Figure 2). 
 
Only one intervention – levothyroxine – showed an improvement in performance on a 
cognitive test assessing memory (matching-to-sample task), when compared to placebo; the 
study assessed the performance of general Army personnel in a cold exposure setting.(9)  
 
A study of triazolam showed either an improvement or no change in terms of performance 
on memory tests, when compared to placebo.(21)  
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Studies comparing carbohydrate supplements to placebo found no difference in performance 
on memory tests.(10-12)  
 
Studies of dexamethasone(16) and scopolamine(25, 26), on the other hand, found reduced 
performance on memory-assessing tests, when compared to placebo.  
 
Vigilance 
 
Eleven RCTs, involving 673 participants, reported results relevant to vigilance (Figure 2). 
 
Temazepam, multivitamin and mineral supplement, caffeine, and melatonin studies showed 
an improvement in performance on vigilance tests, when compared to placebo. A study of 
temazapam, conducted on Army personnel, showed improved performance on psychomotor 
vigilance test.(23) A study comparing the performance of Army personnel taking multivitamin 
and mineral supplements to placebo, found better performance on the visual acuity test in 
the intervention group.(8) Caffeine group performed better than placebo group on 
marksmanship, psychomotor recognition test, urban operation vigilance task, and vigilance 
task/obstacle course.(13, 14) A study of Army personnel found that melatonin group 
performed better than placebo group on dual vigilance task, and simple visual reaction time 
test.(15)  
 
When compared to placebo, carbohydrate supplementation showed either an improvement, 
or no change, depending on the cognitive test used to assess performance in three 
studies.(10-12)  
 
Studies of dexamethasone,(16) creatine supplementation,(20) and triazolam,(21) showed no 
change in performance on vigilance tests when compared to placebo.  
 
DISCUSSION 
 
Sixteen interventions were studied across 22 RCTs. Of those, 7 interventions showed an 
improvement in performance on a cognitive outcome, when compared to either a control or 
placebo: caffeine, levothyroxine, prazosin, multivitamin and mineral, protein, melatonin, 
temazepam. Overall, caffeine provided the most consistent results with an improvement in 
performance compared to placebo on five cognitive domains: action control, decision-
making, self-regulation and executive function, vigilance and co-action. Levothyroxine 
showed improvement on 4 cognitive domains: alertness, attention, self-regulation and 
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executive function, and finally, prazosin showed improvement in 3 cognitive domains: 
alertness, attention, and self-regulation and executive function. In most of these cases, the 
conditions under which the Army personnel were tested can help to explain the results. In 
the two studies reporting on caffeine included in this review, Army personnel had 
experienced sustained periods of sleep deprivation while undertaking combat tasks. It is 
well-established that caffeine has a beneficial effect on performing tasks over a long period 
of time (i.e. vigilance), reaction times and executive skills such as decision making in sleep-
deprived conditions.(27) Caffeine acts by blocking adenosine to its receptors (in the brain 
and peripheral tissue) thereby reducing drowsiness.(27) In the one study suggesting positive 
effects from levothyroxine (a synthetic replacement of the thyroid hormone T4), Army 
personnel were enduring extreme conditions in Antarctica. People living in Antarctica have 
reported experiencing symptoms characteristic of hypothyroidism with changes in mood 
(including depression) and cognition. An elevation in T4 via levothyroxine seemed to improve 
mood and cognition. Similarly, prazosin provides a therapeutic benefit for people with PTSD. 
In this review, the study that tested prazosin showed a benefit in mood outcomes for Army 
personnel diagnosed with PTSD.  
 
Multivitamin and mineral supplements appeared to provide some improvement on two 
cognitive domains (alertness, vigilance) when compared to placebo.(8) This finding was 
derived from one study and viewed cautiously because the authors of the study failed to take 
into account training effects and poorly described the results and tools used to assess 
sleepiness. A similar result was observed with protein supplements (attention, decision-
making).(22) Melatonin and temazepam both showed improvement in one cognitive domain 
– vigilance. (15, 23) In this case, Army personnel were tested under sleep-deprived 
conditions, such as shift-work and sleep-wake challenges. As melatonin and temazepam are 
drugs known to induce sleepiness and muscle relaxation, the studies showed that those 
personnel receiving the drugs during the allocated sleep time were able to perform better 
during test time than those without the drugs. The remainder of interventions studied showed 
improvement in no cognitive domains: phenformin/lactose, triazolam, pyridostigmine 
bromide, montelukast sodium, dexamethasone, carbohydrate, creatine, iron, scopolamine. 
 
It needs to be emphasised that the findings of this systematic review are not unequivocal – 
interventions that showed improvement on one domain, often showed no difference or mixed 
results in other cognitive domains. For example, whilst caffeine showed improvement in 
performance on five cognitive domains (action control, decision-making, self-regulation and 
executive function, vigilance and co-action), it also showed mixed results – that is, showing 
improvement and no difference in performance – in alertness and attention. Similarly, 
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although melatonin showed improvement in vigilance, it showed mixed results in attention 
and alertness domains. In addition, the results for each intervention were summarised using 
a vote-counting method which is recognised as a suboptimal way to synthesise 
information.(6) However, as the data in the included studies were poorly reported, counting 
the number of ‘positive’ and ‘negative’ results was seen as the most pragmatic solution to 
synthesise and present highly heterogeneous information.  
 
Additionally, many of the 16 interventions have not been investigated in the past 10 years, 
raising questions about their popularity, utility, or effectiveness as cognitive enhancement 
tools in the Army population. However, the lack of peer-reviewed publications on 
pharmacologicals and biotechnologies on cognitive performance in Army personnel does not 
necessarily mean that these interventions have not been investigated – it may, instead, 
suggest that the results are not available in the public domain.  
 
Study findings are derived from cognitive testing that was neither consistent nor 
comprehensive. The use of individual cognitive tests was poor, with often only a single test, 
or a sub-scale of a test, used to generate conclusions about a cognitive outcome. The 
cognitive tests utilised to evaluate the interventions studied were also generally aimed at a 
general population – studies did not use Army population-specific cognitive tests, such as 
the Automated Neuropsychological Assessment Metrics (ANAM), for example. It is unclear 
whether the findings of non-Army-specific – or at least military-specific – tests are fully 
generalisable to the Army population.  
 
Studies also generally did not systematically report safety outcomes. Where the safety 
outcomes were reported, they included both physical and mental adverse events, and 
ranged from relatively minor (e.g., discomfort, dry mouth) to serious (e.g., suicidal ideation or 
attempt).(7, 8, 16, 17, 24, 28) Because the popularity of enhancers is growing, and the 
adverse events have a negative impact on individual health – and the more serious adverse 
events on unit cohesion – a more systematic approach to the collection of this information 
should be considered.  
 
 
Finally, the included studies did not address the ethical issues around their use – such as 
individual autonomy, consent, benefit to the army, and so forth. The paucity of search results 
of articles on ethics issues pertaining to pharmacologicals and biotechnologies around 
enhancement in general, and their use in the Army population in particular, may be due to 
several reasons. These may include: existence of the research but its unavailability to the 
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public due to the research being classified; lack of interest from researchers (Army or 
civilian) in publishing such articles; non-indexing of the journals which publish such articles in 
the databases searched; or gaps in search strategy. In light of the popularity of enhancers, 
questions will continue to arise about the ethical acceptability of their adoption. 
Collaborations between Army and civilian researchers may be an ideal approach towards 
filling this knowledge gap. 
  
CONCLUSIONS 
 
The inconsistency of results, variety of interventions studied, paucity of reporting on adverse 
events, ethical considerations, and lack of long-term follow-up, preclude positive 
recommendations for any of the enhancers evaluated in the included studies. The findings 
also need to be interpreted with considerable caution. Future studies should include 
outcome such as acute and long-term adverse events, and evaluate cognitive performance 
using cognitive tests that are specific to the Army population. 
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Table 1: Characteristics of included studies 
Author & 
year 
Population Country Sample 
size 
Setting / Indication 
(coded test condition) 
Intervention Comparator Cognitive measures used Safety 
outcomes 
Ethics of the 
use of the 
intervention 
ANTI-DIABETIC (NB. Removed from the market in 1978 by the FDA) 
Phenformin / lactose 
Stamper 
1973 (28) 
Army USA 30 High altitude / acute 
mountain sickness (i.e. 
environmental challenge) 
Phenformin / 
lactose 
Placebo Arousal levels Somatic 
discomfort 
symptoms 
NR 
ANTI-HYPERTENSIVE (treats high blood pressure, anxiety and post-traumatic stress disorder (PTSD)) 
Prazosin 
Raskind 2013 
(7) 
Army USA 67 NR / PTSD (i.e. other) Prazosin Placebo Sleep quality; Global function; 
Clinician Administered PTSD 
Scale; hyperarousal cluster 
Serious 
Adverse Events 
(suicide 
attempts); other 
Adverse Events 
NR 
BENZODIAZEPINES (short-term mediation for insomnia and anxiety, and has muscle relaxant properties) 
Temazepam 
Caldwell 
2003 (23) 
Army - Air USA 16 Shift (night) work (i.e. 
sleep-wake challenges) 
Temazepam Placebo PVT;  POMS; Flight performance 
(simulated); EOG; EMG-sleep 
data 
NR NR 
Triazolam 
Penetar 1989 
(21) 
Army - Air USA 68 Long range air flight (i.e. 
sleep-wake challenges) 
Triazolam Placebo Symbol digit modalities test; trail 
making test; letter cancellation 
test; logical memory portion of the 
Wechsler Memory Scale; five-
item map recall test; POMS; 
Stanford sleepiness scale 
NR NR 
CHOLINESTERASE INHIBITOR (reversible, treats muscle weakness) 
Pyridostigmine bromide, diethyltoluamide, and permethrin 
Roy 2006 
(24) 
Army USA 64 Under both stress and 
rest conditions in a 
supervised clinical 
research unit (i.e. other) 
Pyridostigmin
e bromide, 
diethyltolu-
amide, and 
permethrin 
Placebo Neurocognitive battery: NASA-1 
Spaceflight Cognitive 
Assessment Tool for Windows 
(WinSCAT) measuring code 
Adverse Events NR 
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memory, code matching, running 
memory, matching, and math 
HORMONES 
Melatonin 
Comperatore 
1996 (15) 
Army - Air USA 29 Maintaining stable 
sleep/wake cycles during 
a training mission 
involving rapid 
deployment to the Middle 
East (from USA) and 
night operations (i.e. 
sleep-wake challenges) 
Melatonin Placebo Sleep-wake cycle; Sleep duration; 
POMS; Simple reaction time; 
Four choice reaction time; 
Vigilance test 
NR NR 
Levothyroxine 
Reed 2001 
(9) 
Army USA 12 Antarctic residence (i.e. 
environmental 
challenges) 
Levothyroxine Placebo Matching-to-sample task (test of 
attention, spatial and 
short-term memory, and pattern 
recognition); POMS  
NR NR 
LEUKOTRIENE RECEPTOR ANTAGONIST (commonly used for asthma) 
Montelukast sodium 
Muza 2004 
(18) 
 
 
  
Army USA 12 High altitude - Acute 
Mountain Sickness (i.e. 
environmental 
challenges) 
Montelukast 
sodium 
Placebo Environmental Symptoms 
Questionnaire, Lake Louise Acute 
Mountain Sickness Scoring 
System  
NR NR 
 
 
  
STEROIDS 
Dexamethasone 
Jobe 1991 
(16) 
Army USA 16 High altitude (i.e. 
environmental 
challenges) 
Dexamethaso
ne 
Placebo Affect (Clyde Mood Scale; 
multiple affect adjective check 
list); Cognitive performance: 
coding; addition; pattern 
comparison; Tower of Hanoi; 
computer interaction tasks 
Dizziness NR 
Rock 1989 
(17) 
Army USA 28 Simulated altitude / 
prophylaxis for acute 
mountain sickness (i.e. 
Dexamethaso
ne 
Placebo Environmental Symptoms 
Questionnaire; Acute Mountain 
Sickness - Cerebral symptoms; 
Adrenal 
suppression at 
48 hours post 
NR 
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environmental 
challenges) 
headache; nausea; dyspnea; 
sleep disturbances 
exposure to 
steroids 
STIMULANTS 
Caffeine 
McLellan 
2005 (13) 
Army Canada 30 Sustained 55-hour field 
exercise + sleep deprived. 
(i.e. combat tasks) 
Caffeine Placebo PVT; marksmanship; urban 
operation vigilance test 
NR NR 
McLellan 
2007 (14) 
Army - 
Special 
Forces 
Canada 20 Sustained operations 
training - sustained 
wakefulness and 
restricted daytime sleep 
(i.e. combat tasks) 
Caffeine Placebo Vigilance task NR NR 
SUPPLEMENTS 
Carbohydrate supplements 
Lieberman 
2002 (10) 
Army - 
SEAL 
USA 143 Simulated military mission 
(i.e. combat tasks) 
Carbohydrate 
supplement 
Placebo Vigilance (reaction time); POMS 
(vigour-activity; fatigue-inertia; 
confusion-bewilderment) 
NR NR 
Montain 1997 
(11) 
Army USA 27 Field training in hot, 
humid conditions (i.e. 
combinations) 
Carbohydrate 
supplement 
Placebo Marksmanship; POMS NR NR 
Morgan 2009 
(12) 
Army - 
Special 
Forces 
USA 132 Sustained psychological 
and physical stress during 
Survival School Training. 
(i.e. combat tasks) 
Carbohydrate 
supplement 
Placebo Complex figure copy and recall 
task; digit symbol task; Stroop 
task; letter cancellation tasks; 
Rey auditory verbal learning task; 
California verbal learning task 
NR NR 
Creatine supplement 
Warber 2002 
(20) 
Army USA 26 Military training and 
obstacle course (i.e. 
combat tasks) 
Creatine 
supplement 
Placebo Marksmanship; POMS 
(Confusion, etc) 
NR NR 
Iron supplement 
McClung 
2009 (19) 
Army USA 219 Basic combat training (i.e. 
combat tasks) 
Iron 
supplement 
Placebo POMS (vigour, fatigue, confusion) NR NR 
Multivitamin and mineral supplement 
Li 2013 (8) Army China 240 Endurance military 
training (i.e. combat 
tasks) 
Multivitamin 
and mineral 
supplement 
Placebo Psychological assessment: 
sleepiness; tiredness; visual 
fatigue; total stress 
Somatisation; 
Obsessive-
Compulsive 
behaviour: 
phobic anxiety 
NR 
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(amongst other 
psychological 
sequelae) 
Protein supplement 
Jimenez-
Flores 2012 
(22) 
Army USA 35 Simulated mountain 
skirmishes (i.e. combat 
tasks) 
Protein 
supplement 
Carbohydrate 
supplement 
Choice reaction time test  NR NR 
TROPANE ALKALOIDS (treats motion sickness) 
Scopolamine 
Petersen 
1977 study 1 
(25) 
Army - 
Medical 
USA 24 Evaluating amnestic 
effects of scopolamine - 
information storage and 
retrieval (i.e. none) 
Scopolamine Placebo Recall - 10 lists of words NR NR 
Petersen 
1977 study 2 
(25) 
Army - 
Medical 
USA 18 Evaluating amnestic 
effects of scopolamine - 
information acquisition 
and retrieval (i.e. none) 
Scopolamine Placebo Recall - list of 20 high frequency 
nouns 
NR NR 
Petersen 
1979 (26) 
Army USA 28 State-dependent memory 
and learning (i.e. none)  
Scopolamine Placebo Context-Cued Recall task; Free 
recall; Category recall task 
without cues; Category recall task 
with cues 
NR NR 
PVT = psychomotor vigilance test; NR = not reported; POMS = Profile of Mood States; PTSD = post-traumatic stress disorder; EOG = electrooculography; 
EMG = electromyography; SAE: Serious Adverse Event 
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Appendix 1 – Search strategies 
 
CINAHL search strategy (adapted for searches in CENTRAL, MEDLINE, EMBASE, PsycInfo) 
 
 SEARCH TERM 
CONCEPTS 
FREE TEXT KEYWORDS MESH (CINAHL) 
POPULATION 
 
 
 
 
 
 
Army 
 
 
 
 
Air force* OR airforce* OR air-force* 
Army OR armies 
Militar* 
Navy OR naval OR navies 
paramilitar* OR para-militar* OR para military* 
Soldier* 
Border guard* OR border-guard* 
Gendarmerie* 
Ghurkha* 
(Peace-keeping force*) OR (peacekeeping force*) OR 
(peace keeping force*) 
Pilot* 
War fighter* OR war-fighter* OR warfighter* 
MH “Military Personnel+” 
MH “Military Services+” 
 
INTERVENTION 
 
 
 
 
 
 
 
Biotechnology 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmaceutical 
 
 
 
 
Biologicals 
Biopharmaceutical* 
Bioengineer* OR bio-engineer* 
 
 
 
Drug* 
Illicit drug* 
Pharmaceutical* 
Pharmacological 
 
 
Blood dop* OR blood-dop* 
Cell therap* 
Ergogenic* 
erythropoietin 
growth factor* 
Performance enhanc* OR performance-enhanc* 
 
 
Antioxidant* OR anti-oxidant* 
dietary supplement* 
Electrolyte* 
fortified food* 
functional food* 
Hallucinogen* 
Mineral* 
nootropic* 
nutraceutical* 
orthomolecular 
plant extract* 
Supplement* 
Vitamin* 
 
bacopa monnieri 
MH “Biological Factors+” 
MH “Biological 
Products+” 
MH “Biotechnology” 
MH “Pharmacological 
and Biological 
Treatments+” 
 
 
MH “Drugs+” 
 
 
 
 
MH “Cell therapy” 
MH “Ergogenic Products” 
MH “Erythropoietin” 
MH “Growth 
Substances+” 
MH ”Intercellular 
Signaling Peptides and 
Proteins+” 
 
 
MH “Amino Acids+” 
MH “Antioxidants” 
MH “Dietary 
Supplements+” 
MH “Electrolytes+” 
MH “Fatty Acids, 
Unsaturated+” 
MH “Flavonoids” 
MH “Flavonoids+” 
MH “Food, Fortified” 
MH “Functional Food” 
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Beta blocker* 
brahmi 
cordyceps 
Creatine* 
Dietary protein* 
eurycoma 
Fatty acid* 
Flavonoid* 
ginkgo 
Isoflavone* 
Melatonin* 
omega 3 
panax 
Propanolol* 
Resveratrol* 
rhodiola 
salvia officinalis 
valerian 
 
Alzheimer drug* 
anti-anxiety agent* OR anti anxiety agent* OR 
antianxiety agent* 
Antidepressive agent* OR ant-depressive agent* 
Eugeroic* 
Hypnotic* 
Stimulant* 
 
Acytelcholinesterase inhibitor* 
Adrenergic beta-antagonist* 
Amphetamine* OR methylphenidate* 
Azabicyclo compound* 
Benzhydryl compound* 
Bupropion* 
Caffeine* 
Centrophenoxine* 
Meclofenoxate* 
Memantine* 
Nicotine* 
NMDA receptor agonist* 
NMDA receptor antagonist* 
NMDA receptor modulator* 
Pemoline* 
Phenylalanine* 
Phosphatidylserine* 
Piperazine* 
Piperidine* 
Propranolol* 
Racetam* OR piracetam* OR pramiracetam* OR 
oxiracetam* OR coluracetam* OR aniracetam* OR 
phenylpiracetam* 
Temazepam* 
Theanine* 
tianeptine* 
valproate* 
Valproate* 
Xanthine* 
MH “Hallucinogens+” 
MH “Medicine, Herbal” 
MH “Nootropic Agents+” 
MH “Orthomolecular 
Medicine” 
MH “Plants, Medicinal+” 
MH “Resveratrol” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MH “Adrenergic Beta-
Antagonists+” 
MH “Amphetamines+” 
MH “Antianxiety 
Agents+” 
MH “Caffeine” 
MH “Central Nervous 
System Stimulants+” 
MH “Cholinesterase 
Inhibitors+” 
MH “Dopamine Uptake 
Inhibitors+” 
MH “Melatonin” 
MH “Memantine” 
MH “Methylphenidate” 
MH “Nicotine” 
MH “Phenylalanine” 
MH “Propranolol” 
MH “Xanthines” 
 
 
STUDY TYPES Systematic 
reviews 
SIGN SEARCH FILTER FOR SR’S: 
1: MH “Meta analysis” 
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Randomised 
controlled trials 
Controlled trials 
Cohort studies 
 
2: Meta analys* 
3: Metaanaly* OR meta-analy* 
4: MH “Literature review” 
5: systematic n1 (review or overview) 
6: Or/1-5 
7: PT Commentary 
8: PT Letter 
9: PT Editorial 
10: MH “Animals+” 
11: Or/7-10 
12: 6 NOT 11 
 
SIGN SEARCH FILTER FOR RCTS: 
1: MH "Clinical Trials+" 
2: PT Clinical trial 
3: TX clinic* n1 trial* 
4: TX ((singl* n1 blind*) or (singl* n1 mask*) ) or TX 
((doubl* n1 blind*) or (doubl* n1 mask*)) or TX ((tripl* n1 
blind*) or (tripl* n1 mask*)) or TX ((trebl* n1 blind*) or 
(trebl* n1 mask*)) 
5: TX randomi* control* trial* 
6: MH "Random Assignment" 
7: TX random* allocat* 
8: TX placebo* 
9: MH "Placebos" 
10: MH "Quantitative Studies" 
11: TX allocat* random* 
12: 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
 
SIGN SEARCH FILTER FOR  OBSERVATIONAL 
STUDIES: 
1: MH “Prospective studies+” 
2: MH “Case control studies+” 
3: MH “Correlational studies” 
4: MH “Nonconcurrent prospective studies” 
5: MH “Cross sectional studies” 
6: cohort N1 (study or studies) 
7: observational N1 (study or studies) 
8: OR/1-7 
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Appendix 2 – Risk of Bias assessment  
 
[insert figure 3 here] 
 
 
Figure 3: The Risk of Bias assessment summary for randomised controlled trials included in the systematic review. (A white bar represents 
those studies for which a 'subjective’ or ‘objective’ outcome was not assessed) 



